Abstract
Coronary artery disease is the leading cause of death in Type 2 diabetes patients (T2D) with lipid abnormalities. Fibrates have emerged as second-line agents to reduce circulating triglycerides and elevate HDL-C. The ACCORD Lipid study, a subset of the ACCORD trial([NC0620][1]), investigated
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
